TY - JOUR
T1 - Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer
AU - Peedicayil, Abraham
AU - Vierkant, Robert A.
AU - Shridhar, Vijayalakshmi
AU - Schildkraut, Joellen M.
AU - Armasu, Sebastian
AU - Hartmann, Lynn C.
AU - Fridley, Brooke L.
AU - Cunningham, Julie M.
AU - Phelan, Catherine M.
AU - Sellers, Thomas A.
AU - Goode, Ellen L.
N1 - Funding Information:
We thank Ms. Elaine Elliott for study management, Ms. Karin Goodman and Ms. Ashley Pitzer for subject recruitment, Dr. Mark Liebow for coordination of control recruitment, and Ms. Kristin White for assistance with table preparation. Financial support was provided by R01 CA88868, R01 CA122443, Fraternal Order of Eagles, and Minnesota Ovarian Cancer Alliance.
PY - 2009/8
Y1 - 2009/8
N2 - Objective: We have previously shown that TCEAL7 (transcription elongation factor A (SII)-like 7) is epigenetically down-regulated in the majority of epithelial ovarian cancers. We now examine the hypothesis that inherited alterations in TCEAL7 play a role in the etiology of ovarian cancer. Methods: A two-site case-control study of 930 cases of ovarian cancer and 1037 controls, frequency-matched on residence, age and race, was conducted. Six informative SNPs (tagSNPs and putative-functional SNPs) were genotyped. Logistic regression was used to adjust for potential confounders and determine if inherited variation at this locus was associated with risk of ovarian cancer in general and among cases with invasive disease and serous histology. Gene-level principal component and haplotype analyses were also conducted. Results: None of the SNPs or haplotypes studied were significantly associated with ovarian cancer risk overall. However, among the 440 invasive serous cases, the minor alleles for three correlated SNPs were significantly associated with reduced risk (p-values < 0.05), summarized gene-level variation was weakly associated with reduced risk (p-value = 0.05), and the predominant haplotype was less common among cases than controls (0.36 v 0.40, p-value = 0.05), consistent with single-SNP results. Conclusion: TCEAL7 polymorphisms may play a role in the development of invasive serous ovarian cancers. Follow-up molecular and replication studies are warranted.
AB - Objective: We have previously shown that TCEAL7 (transcription elongation factor A (SII)-like 7) is epigenetically down-regulated in the majority of epithelial ovarian cancers. We now examine the hypothesis that inherited alterations in TCEAL7 play a role in the etiology of ovarian cancer. Methods: A two-site case-control study of 930 cases of ovarian cancer and 1037 controls, frequency-matched on residence, age and race, was conducted. Six informative SNPs (tagSNPs and putative-functional SNPs) were genotyped. Logistic regression was used to adjust for potential confounders and determine if inherited variation at this locus was associated with risk of ovarian cancer in general and among cases with invasive disease and serous histology. Gene-level principal component and haplotype analyses were also conducted. Results: None of the SNPs or haplotypes studied were significantly associated with ovarian cancer risk overall. However, among the 440 invasive serous cases, the minor alleles for three correlated SNPs were significantly associated with reduced risk (p-values < 0.05), summarized gene-level variation was weakly associated with reduced risk (p-value = 0.05), and the predominant haplotype was less common among cases than controls (0.36 v 0.40, p-value = 0.05), consistent with single-SNP results. Conclusion: TCEAL7 polymorphisms may play a role in the development of invasive serous ovarian cancers. Follow-up molecular and replication studies are warranted.
KW - Polymorphism
UR - http://www.scopus.com/inward/record.url?scp=67549098087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67549098087&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2009.03.038
DO - 10.1016/j.ygyno.2009.03.038
M3 - Article
C2 - 19419758
AN - SCOPUS:67549098087
SN - 0090-8258
VL - 114
SP - 260
EP - 264
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 2
ER -